logo-alt.png
Global Protein Tyrosine Kinase 7 Market is estimated with a CAGR of 5.8% during the forecast period - by PMI
June 10, 2021 10:35 ET | PMI
Covina, CA, June 10, 2021 (GLOBE NEWSWIRE) -- The global protein tyrosine kinase 7 market is anticipated to register a CAGR of 5.8%. Tyrosine-protein kinase-like 7, also known as colon carcinoma...
Logo.png
Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma Companies | DelveInsight
May 26, 2021 20:00 ET | DelveInsight Business Research LLP
Los Angeles, USA, May 26, 2021 (GLOBE NEWSWIRE) -- Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma...
logo-alt.png
Global Cancer ALK Inhibitor Market is estimated to be US$ 10.6 billion by 2030 with a CAGR of 22.0% during the forecast period - by PMI
April 16, 2021 10:05 ET | PMI
Covina, CA, April 16, 2021 (GLOBE NEWSWIRE) -- The Global Cancer ALK Inhibitor Market accounted for US$ 1.5 billion in 2020 and is estimated to be US$ 10.6 billion by 2030 and is anticipated to...
Dyadic Logo Current.jpg
UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial
March 29, 2021 08:30 ET | Dyadic International, Inc.
Advancing Dyadic’s proprietary owned COVID-19 vaccine candidate, DYAI-100, towards first-in-human Phase 1 clinical trial Engaged CR2O, a contract research organization, to manage and support further...
BES_Mark.jpg
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against AstraZeneca PLC and Encourages Investors to Contact the Firm
March 26, 2021 21:00 ET | Bragar Eagel & Squire
NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the...
Dyadic Logo Current.jpg
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
March 23, 2021 09:00 ET | Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
Dyadic Logo Current.jpg
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
March 22, 2021 21:00 ET | Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
Dyadic Logo Current.jpg
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
March 22, 2021 08:30 ET | Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca, iRhythm Technologies, Tyson Foods, and Clover Health Investments and Encourages Investors to Contact the Firm
March 17, 2021 15:00 ET | Bragar Eagel & Squire
NEW YORK, March 17, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
logo-alt.png
Global Cancer CDK Inhibitor Market 2019-2029 - Pipeline Analysis is estimated to be US$ 16.1 billion by 2030 with a CAGR of 10.4% during the forecast period - by PMI
March 17, 2021 11:35 ET | PMI
Covina CA, March 17, 2021 (GLOBE NEWSWIRE) -- The Global Cancer CDK Inhibitor Market accounted for US$ 6.0 billion in 2019 and is estimated to be US$ 16.1 billion by 2029 and is anticipated to...